Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France : = Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia

"Severe acute respiratory syndrome" coronavirus 2 (SARS-Cov-2) is a new coronavirus that induces pneumonia called Corona Virus Disease- 19 (COVID-19), an infected 1.5 million people worldwide and caused the more than 85,000 patients died. COVID-19 usually comes in the form of viral pneumonia but with the peculiarities of a risk frequent worsening towards acute respiratory distress syndrome (ARDS) and a usual duration of oxygen dependence in fragile patients by their age or their comorbidities. To date, there is no therapy effective in preventing or treating COVID-19. Drug identification is a major concern and a public health emergency. Retrospective study (Wu 2020) highlighted improved survival in COVID-19 patients with acute ARDS and treated with corticosteroids (CS). So even in the absence of evidence of effectiveness, the SCs are used for COVID-19 oxygen-dependent patients or with an ARDS. However, their benefit / risk remains debated (Russel 2020). On histological samples of COVID-19, diffuse alveolar damage (DAD) has been especially observed (Hanley 2020). DAD is described histologically in an exudative phase, an organizational phase and a irreversible fibrotic phase (Hughes 2017). SC could have an effect beneficial by limiting the exudative / inflammatory phase but also that organization whose histological and CT aspects are sometimes indistinguishable from organized pneumonia, a form of pulmonary repair aberrant very corticosensitive (Travis 2013). Chest scans performed in the face of the persistence or worsening of oxygen dependence beyond the 7th day of COVID-19 symptoms, could help discern indirect complications (pulmonary embolism, exacerbation of COPD, bacterial superinfection, etc.) of an unfavorable course COVID-19 (by displaying an aspect suggesting DAD in particular during the organization phase). We hypothesize that, in the context of COVID-19, the SCs may be beneficial in patients with CT scans thoracic images suggestive of DAD either at the exudat... Full description

Year of Publication: 2020
Published: Bethesda (Maryland), ClinicalTrials.gov, June 4, 2020
Language: English
Full text access: Full text access (free access)
Links: Full Text (clinicaltrials.gov)
Keywords: COVID-19
Clinical Study Status: Not yet recruiting
Clinical Study
Clinical Trial, Phase III
Forschungsbericht
Klinische Studie
Pneumonia > MeSH
Notes: Source: ClinicalTrials.gov (no modifications made)
ClinicalTrials.gov processed this data on June 05, 2020
Last update posted on ClinicalTrials.gov: June 4, 2020
Last updated: 2020-06-08
NCT ID:
    NCT04359511

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03903nam a22004932 4500
001 CTG003370097
003 DE-627
005 20200609024430.0
007 cr uuu---uuuuu
008 200609s2020 xx |||||ot 00| ||eng c
028 5 2 |a CTg_2020-06-08.pp 
035 |a (DE-627)CTG003370097 
035 |a (DE-599)NCTNCT04359511 
035 |a (NCT)CORTI-COVID-19-HUGO 
035 |a (NCT)DR200136 
035 |a (NCT)NCT04359511 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
084 |a PHARMAZIE  |q DE-84  |2 fid 
084 |a pha  |2 ssgn 
245 1 0 |a Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France  |b  = Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia 
246 3 1 |a Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia 
264 1 |a Bethesda (Maryland)  |b ClinicalTrials.gov  |c June 4, 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Source: ClinicalTrials.gov (no modifications made) 
500 |a ClinicalTrials.gov processed this data on June 05, 2020 
500 |a Last update posted on ClinicalTrials.gov: June 4, 2020 
500 |a Last updated: 2020-06-08 
520 |a "Severe acute respiratory syndrome" coronavirus 2 (SARS-Cov-2) is a new coronavirus that induces pneumonia called Corona Virus Disease- 19 (COVID-19), an infected 1.5 million people worldwide and caused the more than 85,000 patients died. COVID-19 usually comes in the form of viral pneumonia but with the peculiarities of a risk frequent worsening towards acute respiratory distress syndrome (ARDS) and a usual duration of oxygen dependence in fragile patients by their age or their comorbidities. To date, there is no therapy effective in preventing or treating COVID-19. Drug identification is a major concern and a public health emergency. Retrospective study (Wu 2020) highlighted improved survival in COVID-19 patients with acute ARDS and treated with corticosteroids (CS). So even in the absence of evidence of effectiveness, the SCs are used for COVID-19 oxygen-dependent patients or with an ARDS. However, their benefit / risk remains debated (Russel 2020). On histological samples of COVID-19, diffuse alveolar damage (DAD) has been especially observed (Hanley 2020). DAD is described histologically in an exudative phase, an organizational phase and a irreversible fibrotic phase (Hughes 2017). SC could have an effect beneficial by limiting the exudative / inflammatory phase but also that organization whose histological and CT aspects are sometimes indistinguishable from organized pneumonia, a form of pulmonary repair aberrant very corticosensitive (Travis 2013). Chest scans performed in the face of the persistence or worsening of oxygen dependence beyond the 7th day of COVID-19 symptoms, could help discern indirect complications (pulmonary embolism, exacerbation of COPD, bacterial superinfection, etc.) of an unfavorable course COVID-19 (by displaying an aspect suggesting DAD in particular during the organization phase). We hypothesize that, in the context of COVID-19, the SCs may be beneficial in patients with CT scans thoracic images suggestive of DAD either at the exudative phase or at the pulmonary organization phase. 
650 4 |a Clinical Study Status: Not yet recruiting 
650 4 |a COVID-19 
650 4 |a Clinical Study 
650 4 |a Klinische Studie 
650 4 |a Clinical Trial, Phase III 
650 4 |a Pneumonia  |x MeSH 
655 7 |a Forschungsbericht  |2 gnd-content 
710 2 |a University Hospital, Tours  |e Herausgebendes Organ  |4 isb 
856 4 0 |u https://clinicaltrials.gov/show/NCT04359511  |z Kostenfrei  |3 Volltext 
912 |a GBV_CTG 
936 u w |j 2020  |b 4  |c 06 
951 |a BO 
952 |j 2020  |b 4  |c 06